ENTITY
LianBio

LianBio (LIAN US)

15
Analysis
Health CareUnited States
LianBio operates as a biological technology company. The Company develops therapies to treat cardiovascular, oncology, respiratory, ophthalmology and inflammatory disease. LianBio serves customers patients in Asia.
more
bullishLianBio
30 Jan 2024 20:51Syndicated

Lianbio -Ads (LIAN) - Tuesday, Oct 31, 2023

The company recently sold exclusive rights to develop and commercialize mavacamten in certain areas of Asia to Bristol Myers Squibb for $350 million.

Logo
208 Views
Share
21 Dec 2023 09:30

2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...

Logo
604 Views
Share
bearishLianBio
04 Sep 2023 09:10

LianBio (LIAN.US) - Some Points Worth the Attention

LianBio's pipeline is good, but there’s an “insurmountable obstacle” to license-in mode, making it hard to be breakeven. Approval of Mavacamten is...

Logo
393 Views
Share
bullishLianBio
01 Sep 2023 17:39

LianBio (LIAN US): Lead Asset Is Approaching Commercialization; Satisfactory Cash Runway

​LianBio's lead asset mavacamten is undergoing review in China for symptomatic obstructive hypertrophic cardiomyopathy, with approval expected in...

Logo
572 Views
Share
bullishLianBio
18 Apr 2023 17:32

LianBio (LIAN US): 2023 Is Going to Be Data Heavy; Current Cash Runway Raises Commercialization Hope

This year, LianBio expects to report late-stage trial data, initiate clinical trials, and file marketing approval for lead drug candidate in China....

Logo
379 Views
Share
x